Rat Glaucoma Model

Disrupting aqueous humor drainage causes intraocular pressure to rise, creating the central physiological stress used in this model. Sustained pressure elevation can then be examined alongside retinal ganglion cell loss and optic nerve damage. This relationship allows researchers to study how altered ocular fluid dynamics are associated with progressive neurodegeneration rather than examining pressure as an isolated measurement.

Retinal ganglion cell loss and optic nerve damage represent related but distinct indicators of neural injury. Assessing both helps researchers connect cellular degeneration in the retina with structural damage along the pathway carrying visual information. Their combined evaluation strengthens interpretation of disease progression and helps determine whether an intervention preserves neural tissue beyond simply lowering intraocular pressure.

The model supports separate evaluation of therapies that reduce intraocular pressure and treatments intended to protect neurons from degeneration. Researchers can compare pressure measurements with retinal structure, visual function, and markers of neural damage over time. A treatment that improves pressure but does not preserve retinal or optic nerve outcomes may have a different biological effect from a genuinely neuroprotective approach.

After researchers disrupt aqueous humor drainage, they follow the animals over time rather than relying on a single endpoint. Monitoring can include intraocular pressure, retinal structure, visual function, and neurodegeneration. This longitudinal approach reveals how pressure changes relate to later tissue injury and functional impairment, providing a fuller picture of disease development and treatment response.

Imaging methods can document changes in retinal structure and support repeated assessment of tissue condition during disease progression. Biomarkers provide additional indicators of cellular responses or neurodegeneration that may not be captured by pressure measurements alone. Together, these readouts can help evaluate candidate monitoring tools and identify changes relevant to progression or therapeutic response.

Researchers use this system when they need to investigate glaucoma pathophysiology, follow cellular responses associated with vision loss, or test candidate interventions before clinical research. Its applications include pressure-lowering therapies, neuroprotective treatments, imaging methods, and biomarkers. The model therefore connects biological mechanisms with measurable structural, functional, and degenerative outcomes in a controlled experimental setting.